This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435–9.
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–42.
Haigh JJ. Role of VEGF in organogenesis. Organogenesis. 2008;4:247–56.
Andraweera PH, Dekker GA, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update. 2012;18:436–57.
Andraweera PH, Dekker GA, Laurence JA, Roberts CT. Placental expression of VEGF family mRNA in adverse pregnancy outcomes. Placenta. 2012;33:467–72.
Ong AY, Kiire CA, Frise C, Bakr Y, de Silva SR. Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature. Eye. 2023:1–3. https://doi.org/10.1038/s41433-023-02811-6.
Pentšuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res Part B Dev Reprod Toxicol. 2009;86:328–44.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
Brambell FW, Hemmings WA, Oakley CL. The relative transmission of natural and pepsin-refined homologous antitoxin from the uterine cavity to the foetal circulation in the rabbit. Proc R Soc Lond Ser B Biol Sci. 1959;150:312–7.
Miller RK, Mace K, Polliotti B, DeRita R, Hall W, Treacy G. Marginal transfer of ReoPro™(Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta. 2003;24:727–38.
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–33.
FDA – USA. Faricimab prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf.
Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. Int Immunol. 2001;13:993–1002.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847.
Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–6.
Carneiro ÂM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25–30.
Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454–9.
European Medicines Agency – European Public Assessment Report. Vabysmo. 2022; 101. https://www.ema.europa.eu/en/documents/assessment-report/vabysmo-epar-public-assessment-report_en.pdf.
FDA – USA. Bevacizumab toxicology data. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_Toxr.pdf.
FDA – USA. Aflibercept review. 2019 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125387Orig1s061.pdf.
European Medicines Agency – European Public Assessment Report Variation. Lucentis. 2011 https://www.ema.europa.eu/en/documents/variation-report/lucentis-h-c-715-ii-0020-epar-assessment-report-variation_en.pdf.
FDA – USA. Faricimab pharmacology/toxicology review. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761235Orig1s000PharmR.pdf.
Author information
Authors and Affiliations
Contributions
KG conceived the work, KG/FB/AB/AJ acquired data, all authors reviewed/interpreted data, KG/FB/AB/AJ contributed to drafting the manuscript. KG/ND revised the manuscript. All authors approved the final version and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gallagher, K., Brown, F., Bilal, A. et al. The use of anti-VEGF agents in pregnancy. Eye 38, 1614–1615 (2024). https://doi.org/10.1038/s41433-024-02992-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-024-02992-8